Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Percheron Therapeutics ( (AU:PER) ) has shared an update.
Percheron Therapeutics Limited announced a change in the director’s interest, specifically involving Ben Gil Price. On March 18, 2025, unquoted options expired, and by March 31, 2025, the director acquired 5,000,000 fully paid ordinary shares, increasing his total holdings to 5,999,805 shares. This change reflects a strategic move in the director’s investment, potentially impacting the company’s market perception and stakeholder interests.
More about Percheron Therapeutics
Percheron Therapeutics Limited operates in the biotechnology industry, focusing on the development and commercialization of therapeutic products. The company is involved in advancing medical treatments and solutions, catering to a range of healthcare needs.
Technical Sentiment Signal: Sell
Current Market Cap: $7.52M
Find detailed analytics on PER stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue